Merck & Co (NY:MRK)

144.30 +0.49 (+0.34%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

99 100 Next >

Constitutional Cliffhanger: Supreme Court Set to Rule on Executive Tariff Power as Market Braces for Margin Volatility

January 28, 2026

As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and...

Via MarketMinute

The $4 Billion Avatar: How Synthesia is Defining the Era of Agentic Enterprise Media

January 28, 2026

In a landmark moment for the synthetic media landscape, London-based AI powerhouse Synthesia has reached a staggering $4 billion valuation following a $200 million Series E funding round. Announced on...

Via TokenRing AI

Topics Artificial Intelligence

Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock ↗

January 24, 2026

Via Chartmill

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗

January 21, 2026

Via Stocktwits

FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency

January 28, 2026

In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial...

Via TokenRing AI

Topics Artificial Intelligence Economy

Merck Announces Second-Quarter 2026 Dividend

January 27, 2026

From Merck & Co., Inc.

Via Business Wire

2 Pharmaceutical Stocks Set to Rebound in 2026 ↗

January 27, 2026

There might be massive upside ahead for these drugmakers.

Via The Motley Fool

Why Revolution Medicines Stock Plummeted by Almost 17% Today ↗

January 26, 2026

It doesn't look like the company will end up in the arms of an acquirer soon, after all.

Via The Motley Fool

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse ↗

January 26, 2026

Merck (NYSE: MRK) reportedly ends discussions to acquire Revolution Medicines (NASDAQ: RVMD) after valuation disagreement.

Via Benzinga

Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗

January 26, 2026

Via Stocktwits

Topics Economy Stocks

Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity ↗

January 26, 2026

Stifel expects dip-buyers to step in, saying it would be surprised to see RVMD settle meaningfully below $100, calling the failed talks an “M&A clearing event.”

Via Stocktwits

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Via The Motley Fool

Topics ETFs Intellectual Property World Trade

2 Dirt Cheap Stocks to Buy With $200 Right Now ↗

January 24, 2026

These healthcare leaders seem attractive right now.

Via The Motley Fool

Topics Artificial Intelligence

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

January 23, 2026

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

Via The Motley Fool

2 Soaring Stocks to Hold for the Next 20 Years ↗

January 23, 2026

They can power outstanding returns while providing stability to a well-diversified portfolio.

Via The Motley Fool

Topics Intellectual Property World Trade

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

I Correctly Predicted That These 15 Dow Jones Stocks Would Boost Their Payouts in 2025. Here's Why It Can Happen Again in 2026. ↗

January 22, 2026

The Dow is chock-full of high-quality companies that pay growing dividends.

Via The Motley Fool

Topics Stocks

Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally

January 22, 2026

In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for...

Via MarketMinute

Topics Intellectual Property

Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth

January 22, 2026

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...

Via MarketMinute

Topics Earnings Economy Intellectual Property

Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse

January 22, 2026

As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm

January 21, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and...

Via StockStory

Topics Economy Stocks

Why Moderna Stock Surged Today ↗

January 21, 2026

The vaccine maker is expanding beyond its COVID-focused offerings.

Via The Motley Fool

Merck Shares Rise On $30M Funding From CEPI To Develop Affordable Ebola Vaccine ↗

January 21, 2026

CEPI will provide Merck with $30 million and Merck will, in turn, leverage its joint venture with Wellcome, called Hilleman Laboratories, to develop an Ebola vaccine with an updated manufacturing...

Via Stocktwits

Topics Workforce

Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious ↗

January 20, 2026

BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges.

Via Stocktwits

Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗

January 20, 2026

Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said.

Via Stocktwits

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

January 20, 2026

In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion....

Via MarketMinute

Topics Intellectual Property

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following

January 20, 2026

Via ACCESS Newswire

3 “Forever Stocks” to Hold When the Market Won’t Sit Still ↗

January 19, 2026

Via MarketBeat

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.